SUPPRELIN® LA -
Designed for You and Your Patients

Once-yearly dosing offers flexibility

  • Missing appointments unrelated to SUPPRELIN® LA insertion and removal will not interrupt the 12-month LH suppression1
    • As part of clinical practice, it is recommended that height, bone age, and hormone levels be measured on an ongoing basis
  • May reduce the number of administrations of a GnRH agonist

Once-yearly therapy without titration1

  • The approved dose is one 50-mg implant, surgically inserted subcutaneously into the upper arm once every 12 months
  • Histrelin release (approximately 65 μg/d) is sufficient to inhibit LH release for 12 months—no need for titration
  • Removal of SUPPRELIN® LA at any time will stop delivery of histrelin which should reverse the histrelin-induced suppression

References:
1. SUPPRELIN® LA [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Solutions Inc; 2011.

Next: SUPPRELIN® LA Insertion and Removal

        Indication

        SUPPRELIN® LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP).

        Important Safety Information

        • SUPPRELIN LA is contraindicated in women who are or may become pregnant, and in patients who are hypersensitive to GnRH or GnRH agonist analogs. Safety and effectiveness in pediatric patients under the age of 2 years has not been established.

        • SUPPRELIN LA, like other GnRH agonists, initially causes a transient increase in serum concentrations of estradiol in females and testosterone in both sexes during the first week of treatment, with worsening or onset of new symptoms during this period. Within 4 weeks of therapy, gonadal steroid suppression occurs and manifestations of puberty decrease.

        • Implant insertion and removal is a surgical procedure and should utilize aseptic technique. Careful adherence to the recommended insertion and removal procedures is recommended. On occasion, localizing and/or removal of implant products have been difficult and imaging techniques were used, including ultrasound, CT, or MRI (this implant is not radiopaque).

        • Rare events of spontaneous extrusion have been observed in clinical trials.

        • LH, FSH and estradiol or testosterone should be monitored at 1 month post implantation then every 6 months. Every 6-12 months, height and bone age should also be assessed.

        • In clinical trials, the most common adverse reactions involved the implant site and included bruising, pain, soreness, erythema and swelling.

        Please see the accompanying full Prescribing Information.